A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209.

Affiliation auteurs!!!! Error affiliation !!!!
TitreA randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209.
Type de publicationJournal Article
Year of Publication2018
AuteursSchlumberger M, Newbold K, Hasan B, Marreaud S, Assele S, Licitra LF, Schoffski P, Leboulleux S, Locati L, Godbert Y, Rohmer V, Jarzab B, Domenico S, Bechter OEdgar, Zanetta S, Capdevila J, Kapiteijn E, Bastholt L
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume36
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2018.36.15_suppl.6021